Crown Bioscience enters Japanese market through partnership with Shin Nippon Biomedical Laboratories
Expands the company\'s international footprint following acquisition of Precos in July 2013
Crown Bioscience, a drug discovery and development service company based in Santa Clara, CA in the US, has entered into a partnership with Shin Nippon Biomedical Laboratories (SNBL), a Japanese contract research organisation.
The move will further expand Crown's international footprint following its move into Europe with the acquisition of Precos in July 2013.
The initial focus of the agreement is for SNBL to promote Crown Bioscience services to its Japanese clients, in doing so extending SNBL’s service offering.
As part of the agreement, SNBL will be the exclusive representative for Crown in promoting Crown’s translational science services including the world’s largest collection of Patient Derived Xenograft (PDX) models.
SNBL has multiple facilities across Japan, the US, China, and Cambodia and as such offers Crown access to a global target audience.
While Crown is a leading supplier of oncology services, with a global footprint spanning three major continents in North America, Europe and Asia Pacific, Japan is seen as a market with significant further potential.
Both companies will also look at the potential to co-develop new models and services leveraging their respective expertise in oncology/diabetes and non-human primate model development.
Jean-Pierre Wery, President of Crown, said: 'This strategic partnership offers Crown an excellent opportunity to develop a greater understanding of the Japanese market in order to further develop unique cutting-edge models. It is the first time that SNBL has agreed to represent an overseas company in such a deal. We are delighted to be partnering with the largest preclinical contract research organisation in Japan as part of our international business strategy to develop our services in the Far East.'
Ryoichi Nagata, CEO and President of SNBL, added: 'Our expertise in preclinical development provides a perfect complement to Crown’s existing global services.'
